|
顯示項目 887411-887420 / 2348719 (共234872頁)
<< < 88737 88738 88739 88740 88741 88742 88743 88744 88745 88746 > >>
每頁顯示[10|25|50]項目
| 國立成功大學 |
2024-09 |
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
|
Iwata;Hiroji;Xu;Binghe;Kim;Sung-Bae;Chung;Wei-Pang;Park;Hee, Yeon;Kim;Hwan, Min;Tseng;Ling-Ming;Chung;Chi-Feng;Huang;Chiun-Sheng;Kim;Hyun, Jee;Chiu;Yan, Joanne Wing;Yamashita;Toshinari;Li;Wei;Egorov;Anton;Nishijima;Soichiro;Nakatani;Shunsuke;Nishiyama;Yuji;Sugihara;Masahiro;Cortes;Javier;Im;Seock-Ah |
| 國立成功大學 |
2024-05 |
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial
|
Hurvitz;S, A.;Kim;S, -B.;Chung;W, -P.;Im;S, -A.;Park;Y, H.;Hegg;R;Kim;M, -H.;Tseng;L, -M.;Petry;V;Chung;C, -F.;Iwata;H;Hamilton;E;Curigliano;G;Xu;B;Egorov;A;Liu;Y;Cathcart;J;Bako;E;Tecson;K;Verma;S;Cortes;J |
| 國立成功大學 |
2023 |
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|
Hurvitz, S.A.;Hegg, R.;Chung, W.-P.;Im, S.-A.;Jacot, W.;Ganju, V.;Chiu, J.W.Y.;Xu, B.;Hamilton, E.;Madhusudan, S.;Iwata, H.;Altintas, S.;Henning, J.-W.;Curigliano, G.;Perez-Garcia, J.M.;Kim, S.-B.;Petry, V.;Huang, C.-S.;Li, W.;Frenel, J.-S.;Antolin, S.;Yeo, W.;Bianchini, G.;Loi, S.;Tsurutani, J.;Egorov, A.;Liu, Y.;Cathcart, J.;Ashfaque, S.;Cort�s, J. |
| 臺大學術典藏 |
2021-06-04T05:10:19Z |
Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study
|
CHIUN-SHENG HUANG; Yang, Youngsen; Kwong, Ava; Chen, Shin-Cheh; Tseng, Ling-Ming; Liu, Mei-Ching; Shen, Kunwei; Wang, Shusen; Ng, Ting-Ying; Feng, Yi; Sun, Guofang; Yan, Iris Renfei; Shao, Zhimin |
| 臺大學術典藏 |
2019 |
Trastuzumab emtansine for residual invasive HER2-positive breast cancer
|
Von Minckwitz G.; CHIUN-SHENG HUANG; Geyer C.E.; Jr.; Singel S.M.; Douthwaite H.; Smitt M.; Tesarowski D.; Lam L.H.; Wu H.; Caremoli E.R.; Shao Z.; W?lfing P.; Crown J.P.; Fasching P.A.; DiGiovanna M.P.; Jackisch C.; Wapnir I.L.; Arce-Salinas C.; Jacot W.; Conlin A.K.; Fischer H.H.; Mano M.S.; Loibl S.; Mamounas E.P.; Untch M.; Wolmark N.; Rastogi P.; Schneeweiss A.; Redondo A.; Von Minckwitz G.;Chiun-Sheng Huang;Mano M.S.;Loibl S.;Mamounas E.P.;Untch M.;Wolmark N.;Rastogi P.;Schneeweiss A.;Redondo A.;Fischer H.H.;Jacot W.;Conlin A.K.;Arce-Salinas C.;Wapnir I.L.;Jackisch C.;Digiovanna M.P.;Fasching P.A.;Crown J.P.;W?Lfing P.;Shao Z.;Caremoli E.R.;Wu H.;Lam L.H.;Tesarowski D.;Smitt M.;Douthwaite H.;Singel S.M.;Geyer C.E.;Jr. |
| 臺大學術典藏 |
2022-04-15T02:33:29Z |
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study
|
Krop, Ian E; Im, Seock-Ah; Barrios, Carlos; Bonnefoi, Hervé; Gralow, Julie; Toi, Masakazu; Ellis, Paul A; Gianni, Luca; Swain, Sandra M; Im, Young-Hyuck; De Laurentiis, Michelino; Nowecki, Zbigniew; CHIUN-SHENG HUANG; Fehrenbacher, Louis; Ito, Yoshinori; Shah, Jigna; Boulet, Thomas; Liu, Haiying; Macharia, Harrison; Trask, Peter; Song, Chunyan; Winer, Eric P; Harbeck, Nadia |
| 國立成功大學 |
2016-10-01 |
Trastuzumab-Related Cardiotoxic Effects in Taiwanese Women A Nationwide Cohort Study
|
Chien, Hsu-Chih; Yang, Yea-Huei Kao; Bai, Jane P. F. |
| 國立成功大學 |
2014-10 |
Trastuzumab-Related Cardiotoxicity Among Breast Cancer Patients in Taiwan
|
Chien, Hsu-Chih; Yang, Yea-Huei Kao; Bai, Jane P. F. |
| 國立成功大學 |
2016-08-17 |
Trastuzumab於臺灣乳癌患者之心臟毒性評估
|
錢叙芝; Chien, Hsu-Chih |
| 高雄醫學大學 |
2009 |
Trastuzumab治療早期乳癌輔助治療之成本效果－系統性回顧
|
陳麗芳;梁永昌.呂瑾立;林双金 ; Agnes LF Chan;Henry WC Leung;Chin-Li Lu;Shun Jin Lin |
顯示項目 887411-887420 / 2348719 (共234872頁)
<< < 88737 88738 88739 88740 88741 88742 88743 88744 88745 88746 > >>
每頁顯示[10|25|50]項目
|
